Form 4: Iovance Biotherapeutics CFO Jean-Marc Bellemin Reports Acquisition of Restricted Stock Units

Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, reports the acquisition of restricted stock units (RSUs) in the company.

Summary

• On March 1, 2024, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, acquired 105,470 and 46,875 Restricted Stock Units (RSUs).
• The RSUs represent a contingent right to receive shares of Iovance Biotherapeutics common stock.
• The first set of RSUs (105,470) will vest over three years, with one-third vesting on the one-year anniversary of the grant date, and the remaining RSUs vesting in eight equal quarterly installments over the subsequent two years, contingent upon continued employment.
• The second set of RSUs (46,875) will vest with 50% on the 6-month anniversary of the grant date and the remaining 50% on the one-year anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing about executive compensation. The acquisition of RSUs can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of RSUs by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's financial performance or future outlook, focusing solely on the reported transactions of RSUs.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of key executives.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotechnology industry.
• Vesting schedules of three years with quarterly installments are also typical.
• Companies like Gilead Sciences, Amgen, and Biogen also use RSUs as part of their executive compensation packages.

Stakeholder Impact

• The RSU grants align the CFO's interests with those of the shareholders, as the value of the RSUs is tied to the company's stock performance.

Key Dates